Long-term intravenous epoetin-α/darbepoetin-α ratio in iron-replete hemodialysis patients

Journal of Nephrology

Volumn 20, Issue 1, 2007, Pages 73-79

  Icardi, Andrea ^a   Sacco, Paolo ^a   Salvatore, Francesca ^a   Romano, Umberto ^a  

^a Ospedale La Colletta   (Italy)

Author keywords

Conversion factor; Darbepoetin ; Epoetin ; Hemoglobin; Intravenous; Stable iron replete hemodialysis patients

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; FERROUS GLUCONATE; FOLIC ACID; FOLINIC ACID; IDROXICOBALAMIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN SYNTHESIS; HORMONE ACTION; HUMAN; INFLAMMATION; IRON DEFICIENCY; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MEGALOCYTOSIS; NUTRITIONAL STATUS; PATIENT MONITORING; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; BLOOD; DOSE RESPONSE; DRUG EFFECT; ECONOMICS; ERYTHROPOIESIS; EUROPE; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; PARATHYROID GLAND; PHYSIOLOGY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; EUROPE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PARATHYROID GLANDS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 34447282036     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89.
2. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003; 20: 1903-7.
3. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50: 702-12.
4. Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin 2003; 19: 430-2.
5. Boven K, Stryker S, Knight J, Thomas A, Van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-53.
6. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37 (Suppl 1): S182-238.
7. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougall IC, Macleod A, Wicek A, Cameron S. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2): ii1-47.
8. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 (Suppl 3): 3-13.
9. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5.
10. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ; European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-7.
11. Macdougall IC. Optimizing the use of erythropoietic agents: pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 (Suppl 5): 66-70.
12. Aljama P, Bommer J, Canaud B, Carrera F, Eckardt KU, Hörl WH, Krediet RT, Locatelli F, Macdougall IC, Wikström B; NESP Usage Guidelines Group. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001; 16 (Suppl 3): 22-8.
13. Nissenson AR. Dosing darbepoetin alfa. Am J Kidney Dis 2002; 40: 872.
14. Barnett AI, Crémieux PY. Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis. Pharmacotherapy 2003; 23: 690-4.
15. Deray G. Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant 2003; 18: 2455-6.
16. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20 (Suppl 3): iii3-24.
17. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2002; 22: S160-5.
18. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant 2003; 18: 362-9.
19. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology 2004; 9: 223-8.
20. Daurgirdas JT. Simplified equations for monitoring Kt/V, PCRn, Ekt/V and ePCRn. Adv Ren Replace Ther 1995; 2: 295-304.
21. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-24.
22. Movilli E, Pertica N, Camerini C, Canarini GC, Brunori G, Scolari F, Maiorca R. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 2002; 39: 850-3.
23. Stirling CM, Patel RK, Simpson K. Haemoglobin target for haemodialysis patients - is it achievable? Nephrol Dial Transplant 2005; 20 (Suppl 5): v268.
24. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339: 578-83.
25. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-46.
26. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99-113.
27. Kaufman J. Choosing the right approach with recombinant human erythropoietin. Clinical Opinions in Renal Anaemia. Prime Medica Limited 2005; 2: 10-2.
28. Alfrey CP, Rice L, Udden MM, Driscoll TB. Neocytolysis: physiological down-regulator of red-cell mass. Lancet 1997; 349: 1389-90.
29. Linde T, Furuland H, Wikstrom B. Effects of switch from subcutaneous to intravenous epoetin alfa administration in hemodialysis patients. J Am Soc Nephrol 2003; 14: 844A.
30. Fullerton L, Bhattacharjee D, Roe SD, Cassidy MJ. Erythropoietin: subcutaneous or intravenous dosing? British Journal of Renal Medicine; Winter 2002/2003: 17-9.
31. Jacobs C, Hörl WH, Macdougall IC, Valderrabano F, Parrondo I, Abraham IL, Segner A. European best practice guidelines 9-13 anaemia management. Nephrol Dial Transplant 2000; 15 (Suppl 4): 33-42.
32. Pizzarelli F, David S, Sala P, Icardi A, Casani A. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC). Am J Kidney Dis 2006; 47: 1027-35.
33. Hori W. IV darbepoetin alfa is more effective than i.v. rHuEPO in maintaining target Hb concentrations in patients with renal anaemia [abstract]. Nephrol Dial Transplant 2002; 17 (Suppl 1): 24.
34. Icardi A, Sacco P, Salvatore F, Romano U. Conversion factor of epoetin-alfa / darbepoetin-alfa administered intravenously in hemodialysis stable patients. Nephrology 2005; 10 (Suppl): A319.
35. Amgen Inc. Aranesp (darbepoetin alfa): prescribing information. Thousand Oaks, CA: Amgen Inc 2002.